参考文献
PubMed=10462204; DOI=10.1007/s11626-999-0115-4
Sramkoski R.M., Pretlow T.G. II, Giaconia J.M., Pretlow T.P., Schwartz S., Sy M.-S., Marengo S.R., Rhim J.S., Zhang D., Jacobberger J.W.
A new human prostate carcinoma cell line, 22Rv1.
In Vitro Cell. Dev. Biol. Anim. 35:403-409(1999)
PubMed=12725112; DOI=10.1385/1-59259-372-0:21
Russell P.J., Kingsley E.A.
Human prostate cancer cell lines.
Methods Mol. Med. 81:21-39(2003)
PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)
PubMed=15486987; DOI=10.1002/pros.20158
Zhao H., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.
Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Prostate 63:187-197(2005)
PubMed=19403664; DOI=10.1128/JVI.00546-09
Knouf E.C., Metzger M.J., Mitchell P.S., Arroyo J.D., Chevillet J.R., Tewari M., Miller A.D.
Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells.
J. Virol. 83:7353-7356(2009)
PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=21248069; DOI=10.1158/0008-5472.CAN-10-1998
Li Y., Alsagabi M., Fan D., Bova G.S., Tewfik A.H., Dehm S.M.
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.
Cancer Res. 71:2108-2117(2011)
PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
DOI=10.5897/IJBMBR2013.0154
Iloki Assanga S.B., Gil-Salido A.A., Lewis Lujan L.M., Rosas-Durazo A., Acosta-Silva A.L., Rivera-Castaneda E.G., Rubio-Pino J.L.
Cell growth curves for different cell lines and their relationship with biological activities.
Int. J. Biotechnol. Mol. Biol. Res. 4:60-70(2013)
PubMed=23117885; DOI=10.1158/0008-5472.CAN-12-3630
Li Y., Chan S.-C., Brand L.J., Hwang T.H., Silverstein K.A.T., Dehm S.M.
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Cancer Res. 73:483-489(2013)
PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)
PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)
PubMed=27271795; DOI=10.1002/pros.23190
Shourideh M., DePriest A., Mohler J.L., Wilson E.M., Koochekpour S.
Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.
Prostate 76:1067-1077(2016)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=28145883; DOI=10.18632/oncotarget.14850
Nouri M., Caradec J., Lubik A.A., Li N., Hollier B.G., Takhar M., Altimirano-Dimas M., Chen M., Roshan-Moniri M., Butler M., Lehman M., Bishop J., Truong S., Huang S.-C., Cochrane D., Cox M., Collins C., Gleave M., Erho N., Alshalafa M., Davicioni E., Nelson C., Gregory-Evans S., Karnes R.J., Jenkins R.B., Klein E.A., Buttyan R.
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Oncotarget 8:18949-18967(2017)
PubMed=28928128; DOI=10.1158/0008-5472.CAN-17-0320
Van Etten J.L., Nyquist M., Li Y., Yang R., Ho Y., Johnson R., Ondigi O., Voytas D.F., Henzler C., Dehm S.M.
Targeting a single alternative polyadenylation site coordinately blocks expression of androgen receptor mRNA splice variants in prostate cancer.
Cancer Res. 77:5228-5235(2017)
PubMed=30629668; DOI=10.1371/journal.pone.0210404
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)
PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132
Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S.M., Gorjala P., Mitra R., Nonn L., Kimbro K.S., Kittles R.
Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines.
Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)
PubMed=31006810; DOI=10.1093/nar/gkz286
Kounatidou E., Nakjang S., McCracken S.R.C., Dehm S.M., Robson C.N., Jones D., Gaughan L.
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities.
Nucleic Acids Res. 47:5634-5647(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=31395879; DOI=10.1038/s41467-019-11415-2
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574.1-3574.11(2019)
PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)
